Zydus Cadila Opens New Fronts In COVID-19 Battle
COVID-19 DNA Vaccine Phase III Data By April
Executive Summary
With seven COVID-19 treatment/prophylactic candidates lined up, India's Zydus Cadila is unleashing all it can to combat the disease. While Phase III data for its DNA vaccine candidate is expected by April, the latest to join the pack is ZYIL1, a novel oral small molecule NLRP3 inhibitor.
You may also be interested in...
Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out
Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues
Can Zydus Cadila’s COVID-19 Vaccine Win First Pediatric Approval In India?
Unless Pfizer or Moderna beat the company to it, Zydus Cadila’s COVID-19 vaccine candidate could be India’s first such jab approved for children. With superior thermostability and proposed economical pricing, it will be one to watch, though a three-dose regimen could be a dampener. Meanwhile, saroglitazar sees slow progress.
Coronavirus Update: Gilead And Zydus Cadila Expand Drugs Available In India
Gilead outlines efforts to expand availability of remdesivir in India while offers for supplies from Russia, Uzbekistan are also on the table. Zydus Cadila has received accelerated approval in India for pegylated interferon alpha-2b in moderate COVID-19 infection in adults.